BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Although recent single-cell omics studies have begun to explore the cellular landscape in CML (Giustacchini et al., 2017; Krishnan et al., 2023; Patel et al., 2022; Zhang et al., 2020), these have largely been limited to measuring single modalities at a time, and thus, multiomic investigation of BCR::ABL1+ LSCs and BCR::ABL1- stem cells from the same patient are currently lacking.